Semler Scientific Stock Price, News & Analysis

Semler Scientific, Inc. (Nasdaq: SMLR) is a U.S.-based medical technology company that also operates a distinctive corporate treasury strategy centered on Bitcoin. The company is described in its public communications as a leader in medical devices and software to combat chronic diseases and as one of the leading corporate holders of Bitcoin. Its common stock is listed on The Nasdaq Stock Market LLC under the symbol SMLR, and it reports as Semler Scientific, Inc. in its SEC filings.

Semler Scientific has adopted Bitcoin as its primary or principal treasury reserve asset. According to multiple press releases and SEC filings, the company uses proceeds from equity offerings, convertible notes and other debt financings, as well as cash flows from operations, to acquire and hold Bitcoin. It tracks the performance of this strategy using key performance indicators such as BTC Yield, BTC Gain and BTC $ Gain, and it maintains a dedicated Bitcoin dashboard on its website as a disclosure channel for information about its Bitcoin holdings and related metrics.

Alongside its Bitcoin treasury activities, Semler Scientific operates healthcare businesses focused on early detection and monitoring of chronic diseases. The company develops and markets technology products and services that assist healthcare providers and other customers in evaluating and treating chronic conditions. Its flagship medical product, QuantaFlo, is repeatedly described in company disclosures as a patented, U.S. Food and Drug Administration (FDA) cleared, rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, including peripheral arterial disease (PAD), and is used by healthcare providers to evaluate patients’ risk of mortality and major adverse cardiovascular events (MACE).

Semler Scientific has also formed CardioVanta, Inc., a wholly owned subsidiary that the company states will comprise its future healthcare business activities focused on early detection of heart failure and cardiac arrhythmia monitoring. In its announcements, Semler Scientific notes that CardioVanta is intended to operate under a software-as-a-service (SAAS) business model and to seek capital from outside investors to fund its initial needs. While CardioVanta concentrates on cardiac technology and care systems, Semler Scientific continues to market its QuantaFlo device and software for early detection of peripheral artery disease as part of its broader chronic disease portfolio.

In its financial communications, Semler Scientific highlights that its healthcare technology solutions business generates cash flows that support its Bitcoin acquisition strategy. The company has reported income from operations from its healthcare activities in prior annual periods while simultaneously expanding its digital asset holdings. It has also disclosed the use of at-the-market equity offering programs and convertible senior notes to raise capital, as well as a master loan agreement with Coinbase Credit Inc. under which loans are intended to be collateralized with a first priority security interest in Bitcoin posted as collateral.

Semler Scientific’s public filings and press releases emphasize its dual focus: on the one hand, developing and marketing medical devices and software aimed at early detection and management of chronic diseases; on the other, accumulating and holding Bitcoin as a long-duration treasury asset. The company presents this dual approach as a platform for growth, with its healthcare operations and Bitcoin strategy described together in its investor communications.

In addition, Semler Scientific has announced a strategic plan to realign its operations and improve operating leverage, including a headcount reduction and curtailment of certain operating expenses, as disclosed in a Form 8-K. The company has also entered into an Agreement and Plan of Merger under which it would be acquired by Strive, Inc. in an all-stock transaction, subject to the terms and conditions set forth in that merger agreement. Multiple Form 8-K filings describe the proposed transaction, related supplemental disclosures and unaudited pro forma financial information, but they also note that the transaction remains subject to closing conditions and stockholder approval.

Business Focus and Segments

Based on its public statements, Semler Scientific’s activities can be viewed in two primary areas:

• Healthcare technology and medical devices: Developing and marketing products and services for early detection and monitoring of chronic diseases, including the QuantaFlo test and the healthcare initiatives housed in CardioVanta, Inc.
• Bitcoin treasury and digital assets: Acquiring and holding Bitcoin as a primary or principal treasury reserve asset, financed through equity offerings, debt instruments and operating cash flows, and monitored using internal KPIs such as BTC Yield.

Regulatory and Reporting Environment

Semler Scientific files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the U.S. Securities and Exchange Commission (SEC). These filings cover both its healthcare operations and its digital asset holdings, including unrealized gains and losses from changes in the fair value of Bitcoin. The company has also disclosed a civil investigative demand from the U.S. Department of Justice (DOJ) and an agreement in principle to settle related claims, as well as its intention to use proceeds from financing arrangements and a collateralized term loan to fund the settlement.

Investors reviewing Semler Scientific typically consider both its role in the medical device and healthcare software space and its position as a corporate holder of Bitcoin. The company’s SEC filings and press releases provide detail on revenues and operating expenses from its healthcare business, the scale and fair value of its Bitcoin holdings, and the structure of its capital-raising activities.